Tirz (GLP-1) Dual Incretin Peptide for Metabolic, Endocrine, and Obesity Research
Tirz is a synthetic dual agonist of the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This novel peptide is of great interest in metabolic and endocrine research, particularly in models involving glucose regulation, energy balance, and weight management pathways.
Product Overview Supplied in lyophilized format, Tirz is available for in vitro and preclinical exploration in models evaluating insulin sensitivity, adipocyte function, and incretin hormone signaling.
Key Research Attributes:
- GLP-1 and GIP Dual Activity: Mimics endogenous incretins to enhance glucose-stimulated insulin secretion and satiety signaling.
- Insulin Sensitivity: Explored in studies assessing improved glucose uptake and pancreatic beta-cell preservation.
- Body Weight Modulation: Utilized in obesity-related research targeting reduced energy intake and enhanced metabolic expenditure.
- Chronic Disease Models: Investigated in laboratory models of metabolic syndrome, type 2 diabetes, and lipid metabolism disorders.
Applications in Scientific Research
- Incretin pathway and peptide hormone signaling studies
- Glucose homeostasis and insulin secretion models
- Obesity and energy regulation research
- Liver lipid metabolism and hepatic steatosis studies
- Endocrinology-focused preclinical experiments
Format and Storage Form: Lyophilized powder Purity: >99% Storage: Store at -20°C in a dry, dark location Reconstitution: Reconstitute with sterile bacteriostatic water under aseptic conditions
Disclaimer: Tirz (GLP-1) is provided exclusively for laboratory-based, in vitro scientific research. It is not intended for human or veterinary use. All handling must comply with institutional and legal safety requirements.
Chemical Makeup
Molecular Formula
- Tirz: C225H348N48O68
Molecular Weight
- Tirz: 4813.5 g/mol
Other Known Titles
- Tirz: LY3298176, Dual GIP/GLP-1 Receptor Agonist
Tirz (GLP-1) is intended for qualified scientific research use only. All purchases are subject to our Terms and Conditions.
MORE INFORMATION
| Purity Percentage | 99% Purity |
|---|---|
| Volume | 10MG |
| Bought This Week | 415 |
| New | No |
| Sale | Yes |
RESEARCH
Tirz Research: Effects, Benefits, and Side Effects
Tirz is a dual-pathway metabolic peptide under investigation for its effects on weight management, glycaemic control, and cardiometabolic risk reduction. Clinical and preclinical research has explored its role in obesity, type 2 diabetes, kidney function, and potential neuroprotective outcomes. Long-term safety data are still evolving, and ongoing studies continue to refine understanding of its benefits, limitations, and side-effect profile. The sources below summarise proposed mechanisms, benefits, and reported adverse effects.
-
Tirz: A Comprehensive Review of Clinical Efficacy, Safety, and Future Implications Provides an in-depth overview of Tirz’s mechanism of action, weight management benefits, glycaemic support, and emerging safety insights.
-
Tirz Slows Progression of Kidney Disease in Type 2 Diabetes Summarises findings showing Tirz may slow the progression of chronic kidney disease in metabolic research models.
-
Adverse Effects with Tirz: Meta-Analysis Protocol BMJ Open protocol discussing a systematic review of Tirz-associated side effects and adverse event trends. Read more
-
Metabolic Benefits of Tirz: A Narrative Review Explores cardiovascular, metabolic, and neuroprotective benefits observed in emerging research. Read more
-
Tirz Shown to Improve Heart Health & Reduce Weight Reviews dual benefits involving significant reductions in body fat and improvements in cardiovascular markers.
-
Three-Year Weight Loss Results from Tirz Long-term clinical data highlighting sustained reductions in body weight over multi-year periods.
-
Neuroprotective Effects of Tirz Examines potential cognitive and neurological benefits observed in preclinical and translational models. Read more
-
Tirz Overview: How It Works, Side Effects, and Cost A full guide covering dosing patterns, administration, mechanism of action, and safety considerations.
-
Tirz Lowers Risk of Death in Type 2 Diabetes Investigates clinical evidence showing reduced all-cause mortality rates among diabetic subjects receiving Tirz.
| Dosage | 5 MG, 10 MG, 15 MG, 20 MG |
|---|---|
| Quantity | 3 Vials, 6 Vials, 9 Vials |
Be the first to review “Tirz (GLP-1 / GIP)”
Related products
GLP Peptides
GLP Peptides
Reviews
There are no reviews yet.